After a slow 2024, the biotech shell company Concentra Biosciences is back, offering to buy four biotechs in the past month ...

GSK, iTeos TIGIT drug belrestotug shows efficacy in PD-L1-high NSCLC trial at ESMO, giving some positive news for the beleaguered class.

Phase III trials continue to validate these therapies: notably, GSK and iTeos launched the GALAXIES Lung-301 Phase III study, evaluating a combination of Belrestotug and Dostarlimab in PD-L1 ...

The demise of iTeos Therapeutics-partnered TIGIT inhibitor belrestotug does not come as a complete surprise, given the well-documented challenges faced by companies developing this class of drug ...

A high-level overview of iTeos Therapeutics, Inc. (ITOS) stock. View (ITOS) real-time stock price, chart, news, analysis, analyst reviews and more.